192 related articles for article (PubMed ID: 26525154)
1. Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Hayashi H; Kita Y; Iihara H; Yanase K; Ohno Y; Hirose C; Yamada M; Todoroki K; Kitaichi K; Minatoguchi S; Itoh Y; Sugiyama T
Biomed Chromatogr; 2016 Jul; 30(7):1150-1154. PubMed ID: 26525154
[TBL] [Abstract][Full Text] [Related]
2. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Xiong X; Zhang Y; Wang Z; Zhou C; Yang P; Du X; Yang L; Liu W
Clin Chim Acta; 2022 Feb; 527():1-10. PubMed ID: 34999058
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.
Sparidans RW; Rosing H; Rood JJM; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():390-398. PubMed ID: 27639128
[No Abstract] [Full Text] [Related]
5. A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study.
Kadi AA; Abdelhameed AS; Darwish HW; Attwa MW; Al-Shakliah NS
Biomed Chromatogr; 2016 Aug; 30(8):1248-55. PubMed ID: 26683307
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography-tandem mass spectrometry and its clinical application.
Ishida T; Naito T; Kawakami J
Biomed Chromatogr; 2015 May; 29(5):643-6. PubMed ID: 25296722
[TBL] [Abstract][Full Text] [Related]
7. A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Faivre L; Gomo C; Mir O; Taieb F; Schoemann-Thomas A; Ropert S; Vidal M; Dusser D; Dauphin A; Goldwasser F; Blanchet B
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2345-50. PubMed ID: 21737360
[TBL] [Abstract][Full Text] [Related]
8. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Mukai Y; Wakamoto A; Hatsuyama T; Yoshida T; Sato H; Fujita A; Inotsume N; Toda T
Ther Drug Monit; 2021 Dec; 43(6):772-779. PubMed ID: 33871406
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: Application to finger-prick clinical blood samples of patients with non-small cell lung cancer.
Irie K; Shobu S; Hiratsuji S; Yamasaki Y; Nanjo S; Kokan C; Hata A; Kaji R; Masago K; Fujita S; Okada Y; Katakami N; Fukushima S
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1087-1088():1-5. PubMed ID: 29689441
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
Chahbouni A; den Burger JC; Vos RM; Sinjewel A; Wilhelm AJ
Ther Drug Monit; 2009 Dec; 31(6):683-7. PubMed ID: 19865001
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
[TBL] [Abstract][Full Text] [Related]
12. A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma.
Svedberg A; Gréen H; Vikström A; Lundeberg J; Vikingsson S
J Pharm Biomed Anal; 2015 Mar; 107():186-95. PubMed ID: 25594896
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Yokoyama Y; Tomatsuri M; Hayashi H; Hirai K; Ono Y; Yamada Y; Todoroki K; Toyo'oka T; Yamada H; Itoh K
J Pharm Biomed Anal; 2014 Feb; 89():227-32. PubMed ID: 24309556
[TBL] [Abstract][Full Text] [Related]
14. Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry.
Wang LZ; Lim MY; Chin TM; Thuya WL; Nye PL; Wong A; Chan SY; Goh BC; Ho PC
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(22):2155-61. PubMed ID: 21703945
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients.
Guan S; Chen X; Wang F; Xin S; Feng W; Zhu X; Liu S; Zhuang W; Zhou S; Huang M; Wang X; Zhang L
J Pharm Biomed Anal; 2019 Aug; 172():364-371. PubMed ID: 31096095
[TBL] [Abstract][Full Text] [Related]
16. UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction.
Maher HM; Alzoman NZ; Shehata SM; Abahussain AO
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Apr; 1049-1050():30-40. PubMed ID: 28260629
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies.
Maher HM; Alzoman NZ; Shehata SM
J Pharm Biomed Anal; 2016 May; 124():216-227. PubMed ID: 26966895
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.
Sparidans RW; van Hoppe S; Rood JJ; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1012-1013():118-23. PubMed ID: 26826475
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies.
Maher HM; Alzoman NZ; Shehata SM
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():100-110. PubMed ID: 27336702
[TBL] [Abstract][Full Text] [Related]
20. Sensitive single quadrupole LC/MS method for determination of lapatinib in human plasma.
Musijowski J; Filist M; Rudzki PJ
Acta Pol Pharm; 2014; 71(6):1029-36. PubMed ID: 25745775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
